Publication|Articles|November 14, 2025
Supplements and Featured Publications
- Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Advertisement
This clinical brief is supported by Celltrion Inc.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD
2
Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
3
emtelligent Turns Unstructured Clinical Data Into Actionable Insights
4
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
5